{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:38:04Z","timestamp":1791945484712,"version":"4.3.4"},"reference-count":199,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100011790","name":"Xiangya Hospital, Central South University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011790","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.phrs.2019.104283","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T12:08:46Z","timestamp":1558613326000},"page":"104283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"special_numbering":"C","title":["The pharmacogenetics of natural products: A pharmacokinetic and pharmacodynamic perspective"],"prefix":"10.1016","volume":"146","author":[{"given":"Tai","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.phrs.2019.104283_bib0005","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2174\/138920112800958805","article-title":"Herb-drug interactions: methods to identify potential influence of genetic variations in genes encoding drug metabolizing enzymes and drug transporters","volume":"13","author":"Hu","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"6","key":"10.1016\/j.phrs.2019.104283_bib0010","doi-asserted-by":"crossref","first-page":"430","DOI":"10.12980\/APJTB.4.2014C1255","article-title":"A recent review on phytochemical constituents and medicinal properties of kesum (Polygonum minus Huds.)","volume":"4","author":"Vikram","year":"2014","journal-title":"Asian Pac. J. Trop. Biomed."},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0015","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.drudis.2015.01.009","article-title":"An analysis of FDA-approved drugs: natural products and their derivatives","volume":"21","author":"Patridge","year":"2016","journal-title":"Drug Discov. Today"},{"issue":"2-3","key":"10.1016\/j.phrs.2019.104283_bib0020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10295-015-1723-5","article-title":"Natural product discovery: past, present, and future","volume":"43","author":"Katz","year":"2016","journal-title":"J. Ind. Microbiol. Biotechnol."},{"key":"10.1016\/j.phrs.2019.104283_bib0025","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-pharmtox-010611-134529","article-title":"Drug transporters in drug efficacy and toxicity","volume":"52","author":"DeGorter","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0030","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2174\/138161210790112674","article-title":"Pharmacogenetics of phase I and phase II drug metabolism","volume":"16","author":"Crettol","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"4","key":"10.1016\/j.phrs.2019.104283_bib0035","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2217\/pgs.12.1","article-title":"Pharmacogenetics of antidepressant drugs: current clinical practice and future directions","volume":"13","author":"Narasimhan","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0040","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1634\/theoncologist.12-2-201","article-title":"Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature","volume":"12","author":"Araujo","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.phrs.2019.104283_bib0045","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fphar.2015.00023","article-title":"Corrigendum: herbal medicines in Brazil: pharmacokinetic profile and potential herb-drug interactions","volume":"6","author":"Mazzari","year":"2015","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2019.104283_bib0050","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00216-008-2291-6","article-title":"Functional pharmacogenetics\/genomics of human cytochromes P450 involved in drug biotransformation","volume":"392","author":"Zanger","year":"2008","journal-title":"Anal. Bioanal. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0055","doi-asserted-by":"crossref","first-page":"E101","DOI":"10.1208\/aapsj080112","article-title":"Cytochrome P450s and other enzymes in drug metabolism and toxicity","volume":"8","author":"Guengerich","year":"2006","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00008571-200401000-00001","article-title":"Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants","volume":"14","author":"Nelson","year":"2004","journal-title":"Pharmacogenetics"},{"issue":"10","key":"10.1016\/j.phrs.2019.104283_bib0065","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1007\/s11427-010-4062-9","article-title":"Phenotype prediction of nonsynonymous single nucleotide polymorphisms in human phase II drug\/xenobiotic metabolizing enzymes: perspectives on molecular evolution","volume":"53","author":"Hao","year":"2010","journal-title":"Sci. China Life Sci."},{"issue":"15-16","key":"10.1016\/j.phrs.2019.104283_bib0070","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.drudis.2011.05.010","article-title":"Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only","volume":"16","author":"Kell","year":"2011","journal-title":"Drug Discov. Today"},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0075","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"International Transporter","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0080","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2174\/138161210790112683","article-title":"Pharmacogenetics of drug transporters","volume":"16","author":"Franke","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"68","key":"10.1016\/j.phrs.2019.104283_bib0085","first-page":"19","article-title":"Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy","volume":"13","author":"Sissung","year":"2012","journal-title":"Discov. Med."},{"issue":"10","key":"10.1016\/j.phrs.2019.104283_bib0090","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.295.10.1135","article-title":"Coffee, CYP1A2 genotype, and risk of myocardial infarction","volume":"295","author":"Cornelis","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2019.104283_bib0095","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1743-7075-7-12","article-title":"Coffee consumption and CYP1A2 genotype in relation to bone mineral density of the proximal femur in elderly men and women: a cohort study","volume":"7","author":"Hallstrom","year":"2010","journal-title":"Nutr. Metab. (Lond)"},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ijc.21296","article-title":"Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers","volume":"118","author":"Nkondjock","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.phrs.2019.104283_bib0105","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1158\/1055-9965.EPI-06-1074","article-title":"The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among BRCA1 mutation carriers","volume":"16","author":"Kotsopoulos","year":"2007","journal-title":"Cancer Epidem. Biomar."},{"issue":"5","key":"10.1016\/j.phrs.2019.104283_bib0110","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1468-1331.2011.03353.x","article-title":"Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson\u2019s disease","volume":"18","author":"Popat","year":"2011","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00008571-199702000-00002","article-title":"Lifestyle and nutritional correlates of cytochrome CYP1A2 activity: inverse associations with plasma lutein and alpha-tocopherol","volume":"7","author":"Le Marchand","year":"1997","journal-title":"Pharmacogenetics"},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0120","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","article-title":"Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects","volume":"116","author":"Ingelman-Sundberg","year":"2007","journal-title":"Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.phrs.2019.104283_bib0125","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/archinte.159.9.989","article-title":"Life-threatening events after theophylline overdose: a 10-year prospective analysis","volume":"159","author":"Shannon","year":"1999","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0130","first-page":"109","article-title":"The effect of CYP1A2 gene polymorphism on the metabolism of theophylline","volume":"15","author":"Xiong","year":"2018","journal-title":"Exp. Ther. Med."},{"issue":"5","key":"10.1016\/j.phrs.2019.104283_bib0135","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0009-9236(03)00013-4","article-title":"Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma","volume":"73","author":"Obase","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.phrs.2019.104283_bib0140","doi-asserted-by":"crossref","first-page":"530","DOI":"10.5483\/BMBRep.2010.43.8.530","article-title":"The effect of CYP1A2 gene polymorphisms on theophylline metabolism and chronic obstructive pulmonary disease in Turkish patients","volume":"43","author":"Uslu","year":"2010","journal-title":"BMB Rep."},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12016-013-8393-8","article-title":"Pharmacotherapy of critical asthma syndrome: current and emerging therapies","volume":"48","author":"Albertson","year":"2015","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104283_bib0150","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/00007691-199610000-00011","article-title":"The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate","volume":"18","author":"Bartoli","year":"1996","journal-title":"Ther. Drug Monit."},{"issue":"5","key":"10.1016\/j.phrs.2019.104283_bib0155","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1084\/jem.20040416","article-title":"Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages","volume":"200","author":"Cosio","year":"2004","journal-title":"J. Exp. Med."},{"issue":"20","key":"10.1016\/j.phrs.2019.104283_bib0160","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJM199711133372002","article-title":"A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma","volume":"337","author":"Evans","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.phrs.2019.104283_bib0165","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1440-1843.2006.00897.x","article-title":"Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year","volume":"11","author":"Zhou","year":"2006","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0170","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1515\/dmdi-2012-0001","article-title":"CYP2A6: genetics, structure, regulation, and function","volume":"27","author":"Raunio","year":"2012","journal-title":"Drug Metabol. Drug Interact."},{"issue":"4","key":"10.1016\/j.phrs.2019.104283_bib0175","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.fct.2005.08.019","article-title":"A safety assessment of coumarin taking into account species-specificity of toxicokinetics","volume":"44","author":"Felter","year":"2006","journal-title":"Food Chem. Toxicol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0180","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/lrb.2005.3.81","article-title":"Pharmacogenomics: its role in re-establishing coumarin as treatment for lymphedema","volume":"3","author":"Farinola","year":"2005","journal-title":"Lymphat. Res. Biol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0185","first-page":"165","article-title":"Advances in pharmacology and toxicology of coumarins","volume":"28","author":"Kong","year":"2012","journal-title":"Chin Pharmacol Bull"},{"issue":"11","key":"10.1016\/j.phrs.2019.104283_bib0190","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/00008571-200311000-00005","article-title":"Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9)","volume":"13","author":"Kiyotani","year":"2003","journal-title":"Pharmacogenetics"},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0195","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2217\/14622416.8.2.151","article-title":"CYP2A6 polymorphisms: is there a role for pharmacogenomics in preventing coumarin-induced hepatotoxicity in lymphedema patients?","volume":"8","author":"Farinola","year":"2007","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0200","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/mnfr.200900281","article-title":"Toxicology and risk assessment of coumarin: focus on human data","volume":"54","author":"Abraham","year":"2010","journal-title":"Mol. Nutr. Food Res."},{"issue":"10-11","key":"10.1016\/j.phrs.2019.104283_bib0205","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s002040050005","article-title":"CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians","volume":"73","author":"Inoue","year":"2000","journal-title":"Arch. Toxicol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0210","first-page":"651","article-title":"A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles","volume":"57","author":"Fernandez-Salguero","year":"1995","journal-title":"Am. J. Hum. Genet."},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0215","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0014-5793(98)01297-6","article-title":"Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase","volume":"438","author":"Oscarson","year":"1998","journal-title":"FEBS Lett."},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2019.104283_bib0220","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1002\/(SICI)1099-1557(199808)7:1+<S45::AID-PDS353>3.0.CO;2-1","article-title":"French pharmacovigilance survey evaluating the hepatic toxicity of coumarin","volume":"7","author":"Andrejak","year":"1998","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"20","key":"10.1016\/j.phrs.2019.104283_bib0225","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1016\/0006-2952(88)90063-9","article-title":"Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine\/sparteine type polymorphism","volume":"37","author":"Fonne-Pfister","year":"1988","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.phrs.2019.104283_bib0230","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/ggi.13007","article-title":"Different clinical effect of four antidementia drugs for Alzheimer\\\"s disease patients depending on white matter severity","volume":"17","author":"Fukui","year":"2017","journal-title":"Geriatr. Gerontol. Int."},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0235","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/FTD.0b013e318282ff02","article-title":"Relationship of CYP2D6, CYP3A, POR, and ABCB1 genotypes with galantamine plasma concentrations","volume":"35","author":"Noetzli","year":"2013","journal-title":"Ther. Drug Monit."},{"issue":"11","key":"10.1016\/j.phrs.2019.104283_bib0240","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-011-1064-x","article-title":"BCHE and CYP2D6 genetic variation in Alzheimer\u2019s disease patients treated with cholinesterase inhibitors","volume":"67","author":"Chianella","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2019.104283_bib0245","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.amjopharm.2011.07.003","article-title":"Cytochrome P450 2D6 Phenotyping in an Elderly Population With Dementia and Response to Galantamine in Dementia: A Pilot Study","volume":"9","author":"Clarke","year":"2011","journal-title":"Am J Geriatr Pharmac"},{"issue":"7","key":"10.1016\/j.phrs.2019.104283_bib0250","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/FPC.0b013e32832e0eac","article-title":"Codeine and morphine pathway","volume":"19","author":"Thorn","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"issue":"5","key":"10.1016\/j.phrs.2019.104283_bib0255","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1373\/clinchem.2014.237412","article-title":"Considerations for the Utility of the CPIC Guideline for CYP2D6 Genotype and Codeine Therapy","volume":"61","author":"Crews","year":"2015","journal-title":"Clin. Chem."},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0260","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/clpt.2011.287","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype","volume":"91","author":"Crews","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0265","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0270","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0009-9236(03)00092-4","article-title":"Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9","volume":"74","author":"Simonsson","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0275","first-page":"1","article-title":"Auto-induction of phase I and phase II metabolism of artemisinin in healthy Chinese subjects after oral administration of a new artemisinin-piperaquine fixed combination","volume":"13","author":"Zang","year":"2014","journal-title":"Malaria J"},{"issue":"6","key":"10.1016\/j.phrs.2019.104283_bib0280","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1124\/mol.104.009019","article-title":"Antimalarial artemisinin drugs induce cytochrome p450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor","volume":"67","author":"Burk","year":"2005","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0285","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.dmpk.2014.10.008","article-title":"Effect of CAR polymorphism on the pharmacokinetics of artemisinin in healthy Chinese subjects","volume":"30","author":"Zang","year":"2015","journal-title":"Drug Metab Pharmacok"},{"issue":"4","key":"10.1016\/j.phrs.2019.104283_bib0290","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1128\/AAC.06009-11","article-title":"PXR Variants and Artemisinin Use in Vietnamese Subjects: Frequency Distribution and Impact on the Interindividual Variability of CYP3A Induction by Artemisinin","volume":"56","author":"Piedade","year":"2012","journal-title":"Antimicrob Agents Ch"},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0295","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1365-2125.1997.00556.x","article-title":"Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine","volume":"43","author":"Zhang","year":"1997","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0300","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00002018-200427010-00003","article-title":"Antimalarial drug toxicity - A review","volume":"27","author":"Taylor","year":"2004","journal-title":"Drug Saf."},{"issue":"10","key":"10.1016\/j.phrs.2019.104283_bib0305","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/clc.4960111012","article-title":"Quinine overdose: review of toxicity and treatment","volume":"11","author":"Goldenberg","year":"1988","journal-title":"Clin. Cardiol."},{"issue":"9","key":"10.1016\/j.phrs.2019.104283_bib0310","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/01.fpc.0000230411.89973.1b","article-title":"CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population","volume":"16","author":"Mirghani","year":"2006","journal-title":"Pharmacogenet Genom"},{"issue":"6","key":"10.1016\/j.phrs.2019.104283_bib0315","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1128\/AAC.45.6.1803-1809.2001","article-title":"Population pharmacokinetics of intramuscular quinine in children with severe malaria","volume":"45","author":"Krishna","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.phrs.2019.104283_bib0320","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJM199808273390907","article-title":"Acute lymphoblastic leukemia","volume":"339","author":"Pui","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0325","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.phrs.2019.104283_bib0330","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/ajhp\/54.15.1755","article-title":"Appropriateness of maximum-dose guidelines for vincristine","volume":"54","author":"McCune","year":"1997","journal-title":"Am. J. Health. Syst. Pharm."},{"issue":"10","key":"10.1016\/j.phrs.2019.104283_bib0335","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1182\/blood-2006-10-054528","article-title":"Ancestry and pharmacogenetics of antileukemic drug toxicity","volume":"109","author":"Kishi","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0340","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/pbc.22845","article-title":"Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia","volume":"56","author":"Egbelakin","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2019.104283_bib0345","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/pbc.21435","article-title":"Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients","volume":"50","author":"Renbarger","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0350","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1046\/j.1365-2141.2003.04430.x","article-title":"CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia","volume":"122","author":"Aplenc","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.phrs.2019.104283_bib0355","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.critrevonc.2017.04.004","article-title":"Vincristine-induced peripheral neuropathy in children with cancer: A systematic review","volume":"114","author":"van de Velde","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0360","first-page":"1","article-title":"Human UGT2B7 catalyzes morphine glucuronidation","volume":"25","author":"Coffman","year":"1997","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0365","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ajh.21051","article-title":"UGT2B7 promoter variant -840G&A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease","volume":"83","author":"Darbari","year":"2008","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0370","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00280-009-1029-2","article-title":"Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer","volume":"65","author":"Fujita","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104283_bib0375","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bcpt.12248","article-title":"Influence of UGT2B7, OPRM1 and ABCB1 gene polymorphisms on postoperative morphine consumption","volume":"115","author":"Bastami","year":"2014","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"9","key":"10.1016\/j.phrs.2019.104283_bib0380","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00228-013-1523-7","article-title":"Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain","volume":"69","author":"De Gregori","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.phrs.2019.104283_bib0385","first-page":"19448","article-title":"The effect of GSTT1, GSTM1 and GSTP1 gene polymorphisms on the susceptibility of age-related cataract in Chinese Han population","volume":"8","author":"Qi","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"9231","key":"10.1016\/j.phrs.2019.104283_bib0390","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S0140-6736(00)02631-3","article-title":"Isothiocyanates, glutathione S-transferase M1 and T1 polymorphisms, and lung-cancer risk: a prospective study of men in Shanghai, China","volume":"356","author":"London","year":"2000","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.phrs.2019.104283_bib0395","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1093\/carcin\/23.12.2055","article-title":"Dietary isothiocyanates, glutathione S-transferase polymorphisms and colorectal cancer risk in the Singapore Chinese Health Study","volume":"23","author":"Seow","year":"2002","journal-title":"Carcinogenesis"},{"issue":"11","key":"10.1016\/j.phrs.2019.104283_bib0400","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/ijc.24583","article-title":"Isothiocyanates, glutathione S-transferase M1 and T1 polymorphisms and gastric cancer risk: a prospective study of men in Shanghai, China","volume":"125","author":"Moy","year":"2009","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0405","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11255-011-0082-z","article-title":"Glutathione S-transferases T1 null genotype is associated with susceptibility to aristolochic acid nephropathy","volume":"44","author":"Chen","year":"2012","journal-title":"Int. Urol. Nephrol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0410","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/1389200023337586","article-title":"Catechol-O-Methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis","volume":"3","author":"Zhu","year":"2002","journal-title":"Curr. Drug Metab."},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0415","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/10408690390826464","article-title":"Tea catechins and polyphenols: Health effects, metabolism, and antioxidant functions","volume":"43","author":"Higdon","year":"2003","journal-title":"Crit Rev Food Sci"},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0420","first-page":"114","article-title":"Genetic Association Between the COMT Genotype and Urinary Levels of Tea Polyphenols and Their Metabolites among Daily Green Tea Drinkers","volume":"1","author":"Inoue-Choi","year":"2010","journal-title":"Int. J. Mol. Epidemiol. Genet."},{"issue":"12","key":"10.1016\/j.phrs.2019.104283_bib0425","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1017\/S0007114511002376","article-title":"Health effects of green tea catechins in overweight and obese men: a randomised controlled cross-over trial","volume":"106","author":"Brown","year":"2011","journal-title":"Brit J Nutr"},{"issue":"6","key":"10.1016\/j.phrs.2019.104283_bib0430","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/mnfr.201100726","article-title":"The impact of the catechol-O-methyltransferase genotype on vascular function and blood pressure after acute green tea ingestion","volume":"56","author":"Miller","year":"2012","journal-title":"Mol. Nutr. Food Res."},{"issue":"4","key":"10.1016\/j.phrs.2019.104283_bib0435","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ijc.11259","article-title":"Green tea and risk of breast cancer in Asian Americans","volume":"106","author":"Wu","year":"2003","journal-title":"Int. J. Cancer"},{"issue":"21","key":"10.1016\/j.phrs.2019.104283_bib0440","first-page":"7526","article-title":"Tea intake, COMT genotype, and breast cancer in Asian-American women","volume":"63","author":"Wu","year":"2003","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0445","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3945\/jn.108.098699","article-title":"Drinking Green Tea Modestly Reduces Breast Cancer Risk","volume":"139","author":"Shrubsole","year":"2009","journal-title":"J. Nutr."},{"key":"10.1016\/j.phrs.2019.104283_bib0450","doi-asserted-by":"crossref","first-page":"29559","DOI":"10.1038\/srep29559","article-title":"Impact of ABCB1 1236C & T-2677G & T-3435C & T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib","volume":"6","author":"Dessilly","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0455","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.clpt.6100095","article-title":"Pharmacogenetics of opioids","volume":"81","author":"Somogyi","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2019.104283_bib0460","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.7314\/APJCP.2013.14.5.2937","article-title":"Gene polymorphisms of OPRM1 A118G and ABCB1 C3435T may influence opioid requirements in Chinese patients with cancer pain","volume":"14","author":"Gong","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"6","key":"10.1016\/j.phrs.2019.104283_bib0465","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jbspin.2006.03.006","article-title":"Colchicine today","volume":"73","author":"Niel","year":"2006","journal-title":"Joint Bone Spine"},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0470","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/09723757.2014.11886224","article-title":"MEFV Mutations and CYP3A4 Polymorphisms Do Not Predict \"Colchicine Responsiveness\" in Familial Mediterranean Fever","volume":"14","author":"Akalin","year":"2014","journal-title":"Int. J. Hum. Genet."},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0475","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.4238\/2013.January.24.2","article-title":"Lack of an effect of CYP3A4 and MDR1 gene polymorphisms on colchicine pharmacogenetics in the treatment of Familial Mediterranean fever","volume":"12","author":"Dogruer","year":"2013","journal-title":"Genet. Mol. Res."},{"issue":"7","key":"10.1016\/j.phrs.2019.104283_bib0480","first-page":"1540","article-title":"Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever","volume":"34","author":"Tufan","year":"2007","journal-title":"J. Rheumatol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0485","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.gene.2012.05.040","article-title":"MDR1 gene polymorphisms may be associated with Behcet\u2019s disease and its colchicum treatment response","volume":"505","author":"Rustemoglu","year":"2012","journal-title":"Gene"},{"issue":"9","key":"10.1016\/j.phrs.2019.104283_bib0490","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3109\/0886022X.2011.605980","article-title":"Association between ABCB1 (MDR1) gene 3435 C&T polymorphism and colchicine unresponsiveness of FMF patients","volume":"33","author":"Ozen","year":"2011","journal-title":"Ren. Fail."},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0495","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/gtmb.2013.0293","article-title":"Relationship Between Response to Colchicine Treatment and MDR1 Polymorphism in Familial Mediterranean Fever Patients","volume":"18","author":"Uludag","year":"2014","journal-title":"Genet Test Mol Bioma"},{"key":"10.1016\/j.phrs.2019.104283_bib0500","article-title":"The influence of polymorphisms in MDR1 on colchicines unresponsiveness in familial Mediterranean fever [abstract], 4th International Congress on Systemic Autoinflammatory Diseases","author":"Gershoni-Baruch","year":"2005","journal-title":"Bethesda"},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4238\/vol10-1gmr824","article-title":"Investigation of ABCB1 gene polymorphism with colchicine response in Behcet\u2019s disease","volume":"10","author":"Saricaoglu","year":"2011","journal-title":"Genet. Mol. Res."},{"issue":"8","key":"10.1016\/j.phrs.2019.104283_bib0510","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2217\/pgs.14.68","article-title":"Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia","volume":"15","author":"Ceppi","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"7","key":"10.1016\/j.phrs.2019.104283_bib0515","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2217\/pgs-2016-0001","article-title":"Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia","volume":"17","author":"Lopez-Lopez","year":"2016","journal-title":"Pharmacogenomics"},{"issue":"6","key":"10.1016\/j.phrs.2019.104283_bib0520","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00280-011-1745-2","article-title":"Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity","volume":"68","author":"Guilhaumou","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104283_bib0525","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/0091270010374472","article-title":"Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast","volume":"51","author":"Mougey","year":"2011","journal-title":"J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2019.104283_bib0530","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra020526","article-title":"Pharmacogenomics-drug disposition, drug targets, and side effects","volume":"348","author":"Evans","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104283_bib0535","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.neuint.2015.07.018","article-title":"Plant alkaloids as drug leads for Alzheimer\u2019s disease","volume":"89","author":"Ng","year":"2015","journal-title":"Neurochem. Int."},{"issue":"15","key":"10.1016\/j.phrs.2019.104283_bib0540","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2217\/pgs.12.152","article-title":"Pharmacogenomics of opioids and perioperative pain management","volume":"13","author":"Sadhasivam","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"1-2","key":"10.1016\/j.phrs.2019.104283_bib0545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pain.2006.01.010","article-title":"Current evidence for a genetic modulation of the response to analgesics","volume":"121","author":"Lotsch","year":"2006","journal-title":"Pain"},{"issue":"10","key":"10.1016\/j.phrs.2019.104283_bib0550","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/j.1399-6576.2004.00517.x","article-title":"The 118 A & G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease","volume":"48","author":"Klepstad","year":"2004","journal-title":"Acta Anaesthesiol. Scand."},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0555","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00000542-200608000-00016","article-title":"Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy","volume":"105","author":"Chou","year":"2006","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0560","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3344\/kjp.2016.29.1.34","article-title":"The Influence of Genotype Polymorphism on Morphine Analgesic Effect for Postoperative Pain in Children","volume":"29","author":"Lee","year":"2016","journal-title":"Korean J. Pain"},{"issue":"5","key":"10.1016\/j.phrs.2019.104283_bib0565","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bcpt.12248","article-title":"Influence of UGT2B7, OPRM1 and ABCB1 Gene Polymorphisms on Postoperative Morphine Consumption","volume":"115","author":"Bastami","year":"2014","journal-title":"Basic Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.phrs.2019.104283_bib0570","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/sj.clpt.6100385","article-title":"Association of ABCB1\/MDR1 and OPRM1 gene polymorphisms with morphine pain relief","volume":"83","author":"Campa","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2019.104283_bib0575","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jpain.2016.02.003","article-title":"Human genetic variability contributes to postoperative morphine consumption","volume":"17","author":"De Gregori","year":"2016","journal-title":"J. Pain"},{"issue":"4","key":"10.1016\/j.phrs.2019.104283_bib0580","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0960-9822(00)00336-5","article-title":"Dopamine modulates acute responses to cocaine, nicotine and ethanol in Drosophila","volume":"10","author":"Bainton","year":"2000","journal-title":"Curr. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2004.05.006","article-title":"The principal features and mechanisms of dopamine modulation in the prefrontal cortex","volume":"74","author":"Seamans","year":"2004","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.phrs.2019.104283_bib0590","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev.neuro.29.051605.113009","article-title":"Neural mechanisms of addiction: the role of reward-related learning and memory","volume":"29","author":"Hyman","year":"2006","journal-title":"Annu. Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.phrs.2019.104283_bib0595","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/npp.2010.208","article-title":"Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse","volume":"36","author":"Moyer","year":"2011","journal-title":"Neuropsychopharmacol"},{"issue":"6","key":"10.1016\/j.phrs.2019.104283_bib0600","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00008571-199712000-00006","article-title":"D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele","volume":"7","author":"Thompson","year":"1997","journal-title":"Pharmacogenetics"},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0605","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neulet.2010.02.021","article-title":"Association analysis between polymorphisms in the dopamine D2 receptor (DRD2) and dopamine transporter (DAT1) genes with cocaine dependence","volume":"473","author":"Lohoff","year":"2010","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0610","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00041444-200509000-00006","article-title":"Association study of dopamine D2 and D3 receptor gene polymorphisms with cocaine dependence","volume":"15","author":"Messas","year":"2005","journal-title":"Psychiatr. Genet."},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0615","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00734999","article-title":"Subclasses of adenosine receptors in the central nervous system: interaction with caffeine and related methylxanthines","volume":"3","author":"Daly","year":"1983","journal-title":"Cell. Mol. Neurobiol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104283_bib0620","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/sj.clpt.6100102","article-title":"A genetic variation in the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep","volume":"81","author":"Retey","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.phrs.2019.104283_bib0625","doi-asserted-by":"crossref","first-page":"967","DOI":"10.5665\/sleep.1962","article-title":"A genome-wide association study of caffeine-related sleep disturbance: confirmation of a role for a common variant in the adenosine receptor","volume":"35","author":"Byrne","year":"2012","journal-title":"Sleep"},{"issue":"6","key":"10.1016\/j.phrs.2019.104283_bib0630","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/j.1476-5381.2011.01689.x","article-title":"Polymorphisms of ADORA2A modulate psychomotor vigilance and the effects of caffeine on neurobehavioural performance and sleep EEG after sleep deprivation","volume":"165","author":"Bodenmann","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.phrs.2019.104283_bib0635","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/sj.npp.1300232","article-title":"Association between A2a receptor gene polymorphisms and caffeine-induced anxiety","volume":"28","author":"Alsene","year":"2003","journal-title":"Neuropsychopharmacol"},{"issue":"12","key":"10.1016\/j.phrs.2019.104283_bib0640","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1038\/npp.2008.17","article-title":"Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety","volume":"33","author":"Childs","year":"2008","journal-title":"Neuropsychopharmacol"},{"issue":"9","key":"10.1016\/j.phrs.2019.104283_bib0645","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1038\/npp.2010.71","article-title":"Association of the Anxiogenic and Alerting Effects of Caffeine with ADORA2A and ADORA1 Polymorphisms and Habitual Level of Caffeine Consumption","volume":"35","author":"Rogers","year":"2010","journal-title":"Neuropsychopharmacol"},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0650","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.nbd.2009.06.009","article-title":"A genetic variation in the ADORA2A gene modifies age at onset in Huntington\u2019s disease","volume":"35","author":"Dhaenens","year":"2009","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0655","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/157488410791110805","article-title":"A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer\u2019s disease, in healthy subjects and patients","volume":"5","author":"Huang","year":"2010","journal-title":"Curr. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.phrs.2019.104283_bib0660","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.phrs.2019.104283_bib0665","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084059","article-title":"CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer\u2019s disease","volume":"8","author":"Weng","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0670","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1055\/s-0035-1545300","article-title":"Association of the choline acetyltransferase gene with responsiveness to acetylcholinesterase inhibitors in Alzheimer\u2019s disease","volume":"48","author":"Yoon","year":"2015","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"10.1016\/j.phrs.2019.104283_bib0675","first-page":"S191","article-title":"Association study between cholineacetyltransferase (ChAT) polymorphism and treatment responses of galantamine in Alzheimer patients","volume":"6","author":"Lee","year":"2010","journal-title":"Alzheimers Dement."},{"issue":"4","key":"10.1016\/j.phrs.2019.104283_bib0680","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/00003081-200112000-00022","article-title":"Soy phytoestrogens: research on benefits and risks","volume":"44","author":"Wagner","year":"2001","journal-title":"Clin. Obstet. Gynecol."},{"issue":"26","key":"10.1016\/j.phrs.2019.104283_bib0685","doi-asserted-by":"crossref","first-page":"7632","DOI":"10.1021\/jf034427b","article-title":"Phytoestrogens modulate binding response of estrogen receptors alpha and beta to the estrogen response element","volume":"51","author":"Kostelac","year":"2003","journal-title":"J. Agric. Food Chem."},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0690","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.taap.2005.03.015","article-title":"Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR)","volume":"209","author":"Jacobs","year":"2005","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104283_bib0695","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1158\/1055-9965.EPI-06-0899","article-title":"Phytoestrogen exposure is associated with circulating sex hormone levels in postmenopausal women and interact with ESR1 and NR1I2 gene variants","volume":"16","author":"Low","year":"2007","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0700","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/01.ede.0000257571.01358.f9","article-title":"Effect of soy isoflavones on endometriosis: interaction with estrogen receptor 2 gene polymorphism","volume":"18","author":"Tsuchiya","year":"2007","journal-title":"Epidemiology"},{"issue":"5","key":"10.1016\/j.phrs.2019.104283_bib0705","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1349-7006.2009.01118.x","article-title":"Isoflavone, polymorphisms in estrogen receptor genes and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians","volume":"100","author":"Iwasaki","year":"2009","journal-title":"Cancer Sci."},{"issue":"6","key":"10.1016\/j.phrs.2019.104283_bib0710","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1213\/ANE.0000000000000675","article-title":"The effect of beta2-adrenoceptor genotype on phenylephrine dose administered during spinal anesthesia for cesarean delivery","volume":"120","author":"Odekon","year":"2015","journal-title":"Anesth. Analg."},{"issue":"6","key":"10.1016\/j.phrs.2019.104283_bib0715","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/00000539-200006000-00024","article-title":"A dose-response study of prophylactic intravenous ephedrine for the prevention of hypotension during spinal anesthesia for cesarean delivery","volume":"90","author":"Ngan Kee","year":"2000","journal-title":"Anesth. Analg."},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0720","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.bpobgyn.2009.11.009","article-title":"Pharmacogenetic influences in obstetric anaesthesia","volume":"24","author":"Landau","year":"2010","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"issue":"4","key":"10.1016\/j.phrs.2019.104283_bib0725","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/00000542-200604000-00006","article-title":"beta2-adrenoceptor genotype affects vasopressor requirements during spinal anesthesia for cesarean delivery","volume":"104","author":"Smiley","year":"2006","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0730","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5144\/0256-4947.2016.29","article-title":"Ephedrine requirements during spinal anesthesia for cesarean delivery in Jordanian parturients: association with beta2-adrenoceptor gene variants","volume":"36","author":"Almustafa","year":"2016","journal-title":"Ann. Saudi Med."},{"issue":"6","key":"10.1016\/j.phrs.2019.104283_bib0735","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1213\/ANE.0b013e3182179424","article-title":"W.D. Ngan Kee, The effect of maternal and fetal beta2-adrenoceptor and nitric oxide synthase genotype on vasopressor requirement and fetal acid-base status during spinal anesthesia for cesarean delivery","volume":"112","author":"Landau","year":"2011","journal-title":"Anesth. Analg."},{"issue":"1-2","key":"10.1016\/j.phrs.2019.104283_bib0740","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/10428199809057599","article-title":"Vinorelbine induces apoptosis and caspase-3 (CPP32) expression in leukemia and lymphoma cells: a comparison with vincristine","volume":"31","author":"Toh","year":"1998","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.phrs.2019.104283_bib0745","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.phrs.2019.104283_bib0750","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2015.0894","article-title":"Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia","volume":"313","author":"Diouf","year":"2015","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0755","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/cpt.506","article-title":"An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia","volume":"101","author":"Stock","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2019.104283_bib0760","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00280-015-2918-1","article-title":"Unique features of trabectedin mechanism of action","volume":"77","author":"Larsen","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2019.104283_bib0765","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ijc.1221","article-title":"Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways","volume":"92","author":"Damia","year":"2001","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.phrs.2019.104283_bib0770","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/91008","article-title":"Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair","volume":"7","author":"Takebayashi","year":"2001","journal-title":"Nat. Med."},{"issue":"16","key":"10.1016\/j.phrs.2019.104283_bib0775","doi-asserted-by":"crossref","first-page":"8155","DOI":"10.1158\/0008-5472.CAN-06-0179","article-title":"Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin","volume":"66","author":"Herrero","year":"2006","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0780","first-page":"322","article-title":"Development of Yondelis (trabectedin, ET-743)","volume":"26","author":"Cuevas","year":"2009","journal-title":"A semisynthetic process solves the supply problem, Nat Prod Rep"},{"issue":"32","key":"10.1016\/j.phrs.2019.104283_bib0785","doi-asserted-by":"crossref","first-page":"13062","DOI":"10.1073\/pnas.0609877104","article-title":"Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743","volume":"104","author":"Soares","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"10.1016\/j.phrs.2019.104283_bib0790","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1002\/cncr.25925","article-title":"ERCC5\/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma","volume":"117","author":"Italiano","year":"2011","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.phrs.2019.104283_bib0795","first-page":"670","article-title":"Major efficacy of trabectedin in 2 metastatic osteosarcoma patients with wild-type Asp1104 ERCC5 tumor status","volume":"36","author":"Gastaud","year":"2013","journal-title":"Onkologie"},{"issue":"5","key":"10.1016\/j.phrs.2019.104283_bib0800","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/annonc\/mdv071","article-title":"Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study","volume":"26","author":"Monk","year":"2015","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0805","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/PPO.0b013e3181cf0204","article-title":"BRCA gene structure and function in tumor suppression: a repair-centric perspective","volume":"16","author":"Murphy","year":"2010","journal-title":"Cancer J."},{"key":"10.1016\/j.phrs.2019.104283_bib0810","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ctrv.2016.09.009","article-title":"Trabectedin as a chemotherapy option for patients with BRCA deficiency","volume":"50","author":"Monk","year":"2016","journal-title":"Cancer Treat. Rev."},{"issue":"10","key":"10.1016\/j.phrs.2019.104283_bib0815","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/15384047.2016.1219812","article-title":"Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma","volume":"17","author":"Miolo","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.phrs.2019.104283_bib0820","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.breast.2017.04.006","article-title":"Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial","volume":"34","author":"Ghouadni","year":"2017","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.phrs.2019.104283_bib0825","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1158\/0008-5472.CAN-04-3469","article-title":"The antifolate activity of tea catechins","volume":"65","author":"Navarro-Peran","year":"2005","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.phrs.2019.104283_bib0830","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.bcp.2011.07.093","article-title":"Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications","volume":"82","author":"Singh","year":"2011","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0835","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/hep.21735","article-title":"Genetic polymorphisms in the methylenetetrahydrofolate reductase and thymidylate synthase genes and risk of hepatocellular carcinoma","volume":"46","author":"Yuan","year":"2007","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.phrs.2019.104283_bib0840","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/carcin\/bgn177","article-title":"Green tea intake, MTHFR\/TYMS genotype and breast cancer risk: the Singapore Chinese Health Study","volume":"29","author":"Inoue","year":"2008","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0845","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00726-010-0600-9","article-title":"Manganese superoxide dismutase: beyond life and death","volume":"42","author":"Holley","year":"2012","journal-title":"Amino Acids"},{"key":"10.1016\/j.phrs.2019.104283_bib0850","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.freeradbiomed.2014.08.026","article-title":"Manganese superoxide dismutase in breast cancer: from molecular mechanisms of gene regulation to biological and clinical significance","volume":"77","author":"Becuwe","year":"2014","journal-title":"Free Radic. Biol. Med."},{"issue":"4","key":"10.1016\/j.phrs.2019.104283_bib0855","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2174\/187152511798120949","article-title":"A review of oxidative stress related genes and new antioxidant therapy in diabetic nephropathy","volume":"9","author":"Makuc","year":"2011","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2019.104283_bib0860","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.coi.2012.04.003","article-title":"Chronic inflammation and aging: DNA damage tips the balance","volume":"24","author":"Cavanagh","year":"2012","journal-title":"Curr. Opin. Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0865","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cell.2012.01.017","article-title":"Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases","volume":"148","author":"Park","year":"2012","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.phrs.2019.104283_bib0870","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10522-015-9561-4","article-title":"The anti-inflammatory effects of resveratrol on human peripheral blood mononuclear cells are influenced by a superoxide dismutase 2 gene polymorphism","volume":"16","author":"Capeleto","year":"2015","journal-title":"Biogerontology"},{"issue":"10","key":"10.1016\/j.phrs.2019.104283_bib0875","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1161\/01.RES.0000267723.65696.4a","article-title":"Sirt1 regulates aging and resistance to oxidative stress in the heart","volume":"100","author":"Alcendor","year":"2007","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.phrs.2019.104283_bib0880","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/npp.2009.217","article-title":"Association of SOD2, a mitochondrial antioxidant enzyme, with gray matter volume shrinkage in alcoholics","volume":"35","author":"Srivastava","year":"2010","journal-title":"Neuropsychopharmacol"},{"issue":"6653","key":"10.1016\/j.phrs.2019.104283_bib0885","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/39885","article-title":"Anterograde transport of brain-derived neurotrophic factor and its role in the brain","volume":"389","author":"Altar","year":"1997","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0890","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1017\/S0029665112000146","article-title":"Flavonoids as modulators of memory and learning: molecular interactions resulting in behavioural effects","volume":"71","author":"Rendeiro","year":"2012","journal-title":"Proc. Nutr. Soc."},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0895","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0092-8674(03)00035-7","article-title":"The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function","volume":"112","author":"Egan","year":"2003","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.phrs.2019.104283_bib0900","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.neuropharm.2009.11.002","article-title":"Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD mice","volume":"58","author":"Hou","year":"2010","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0905","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.neures.2010.11.008","article-title":"Oroxylin A increases BDNF production by activation of MAPK-CREB pathway in rat primary cortical neuronal culture","volume":"69","author":"Jeon","year":"2011","journal-title":"Neurosci. Res."},{"issue":"2","key":"10.1016\/j.phrs.2019.104283_bib0910","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12640-016-9611-y","article-title":"Baicalin attenuates ketamine-induced neurotoxicity in the developing rats: involvement of PI3K\/Akt and CREB\/BDNF\/Bcl-2 pathways","volume":"30","author":"Zuo","year":"2016","journal-title":"Neurotox. Res."},{"issue":"1","key":"10.1016\/j.phrs.2019.104283_bib0915","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/1871527314666150202151440","article-title":"Ginkgo biloba extract 761: a review of basic studies and potential clinical use in psychiatric disorders","volume":"14","author":"Montes","year":"2015","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"8","key":"10.1016\/j.phrs.2019.104283_bib0920","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.biopsych.2012.04.032","article-title":"Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba","volume":"72","author":"Zhang","year":"2012","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.phrs.2019.104283_bib0925","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.tips.2014.02.001","article-title":"Insights into drug discovery from natural medicines using reverse pharmacokinetics","volume":"35","author":"Hao","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0930","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jgr.2014.03.001","article-title":"A review on the medicinal potentials of ginseng and ginsenosides on cardiovascular diseases","volume":"38","author":"Lee","year":"2014","journal-title":"J. Ginseng Res."},{"issue":"6","key":"10.1016\/j.phrs.2019.104283_bib0935","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.biotechadv.2018.02.011","article-title":"The functional genomic studies of resveratrol in respect to its anti-cancer effects","volume":"36","author":"Huminiecki","year":"2018","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.phrs.2019.104283_bib0940","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.semcancer.2017.04.002","article-title":"The functional genomic studies of curcumin","volume":"46","author":"Huminiecki","year":"2017","journal-title":"Semin. Cancer Biol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0945","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2174\/187569212802509988","article-title":"Integrating pharmacogenetics for assessment of herb-drug interactions: has the time come?","volume":"10","author":"Lee","year":"2012","journal-title":"Curr. Pharmacogenomics Person. Med."},{"key":"10.1016\/j.phrs.2019.104283_bib0950","article-title":"HLA\u2010B* 35: 01 Allele Is a Potential Biomarker for Predicting Polygonum multiflorum\u2010Induced Liver Injury in Humans","author":"Li","year":"2019","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.phrs.2019.104283_bib0955","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/FPC.0b013e328303c034","article-title":"Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine","volume":"18","author":"Endo","year":"2008","journal-title":"Pharmacogenet. Genomics"},{"issue":"4","key":"10.1016\/j.phrs.2019.104283_bib0960","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/sj.tpj.6500406","article-title":"Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication","volume":"7","author":"Kirchheiner","year":"2007","journal-title":"Pharmacogenomics J."},{"issue":"6","key":"10.1016\/j.phrs.2019.104283_bib0965","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bcp.2009.05.011","article-title":"Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model","volume":"78","author":"Wu","year":"2009","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.phrs.2019.104283_bib0970","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1124\/dmd.109.027391","article-title":"Characterizing the effects of common UDP glucuronosyltransferase (UGT) 1A6 and UGT1A1 polymorphisms on cis- and trans-resveratrol glucuronidation","volume":"37","author":"Iwuchukwu","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.phrs.2019.104283_bib0975","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/jcpt.12336","article-title":"The influence of ABCB1 polymorphism C3435T on the pharmacokinetics of silibinin","volume":"40","author":"Tan","year":"2015","journal-title":"J. Clin. Pharm. Ther."},{"issue":"12","key":"10.1016\/j.phrs.2019.104283_bib0980","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2217\/pgs.13.124","article-title":"Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rare ABCC2 polymorphism: a case report","volume":"14","author":"Laurenty","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.phrs.2019.104283_bib0985","series-title":"Alcohol, Drugs, Genes, and the Clinical Laboratory : an Overview for Healthcare and Safety Professionals","author":"Dasgupta","year":"2017"},{"issue":"8","key":"10.1016\/j.phrs.2019.104283_bib0990","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/1440-1681.12257","article-title":"Effects of eNOS rs1799983 and ACE rs4646994 polymorphisms on the therapeutic efficacy of salvianolate injection in Chinese patients with coronary heart disease","volume":"41","author":"Fang","year":"2014","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104283_bib0995","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150785","article-title":"Genetic variants of LDLR and PCSK9 associated with variations in response to antihypercholesterolemic effects of armolipid plus with berberine","volume":"11","author":"De Castro-Oros","year":"2016","journal-title":"PLoS One"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819303974?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819303974?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:59:37Z","timestamp":1760911177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819303974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":199,"alternative-id":["S1043661819303974"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104283","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pharmacogenetics of natural products: A pharmacokinetic and pharmacodynamic perspective","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104283"}}